No Need for Lopinavir Dose Adjustment during Pregnancy: a Population Pharmacokinetic and Exposure-Response Analysis in Pregnant and Nonpregnant HIV-Infected Subjects
Ahmed Hamed Salem(Ain Shams University), Graham P. Taylor(NIHR Imperial Biomedical Research Centre), Aksana K. Jones(AbbVie (United States)), Marília Santini-Oliveira(Instituto Evandro Chagas), Angela M. Nilius(AbbVie (United States)), Cheri E. Klein(Abbott (United Kingdom)), Kristine B. Patterson(University of North Carolina at Chapel Hill)
Cited by 0
Related Papers
Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
|Journal of Clinical Oncology|2017|752
Earlier initiation of ART and further decline in mother-to-child HIV transmission rates, 2000–2011
|AIDS|2014|397
Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial
|The Lancet Oncology|2017|378
Treatment of tuberculosis in HIV-infected persons in the era of highly active antiretroviral therapy
|AIDS|2002|359
Penetration of Tenofovir and Emtricitabine in Mucosal Tissues: Implications for Prevention of HIV-1 Transmission
|Science Translational Medicine|2011|352